

Help us learn more about the health of people with multiple sclerosis (MS).

If you have MS and just started treatment with OCREVUS® (ocrelizumab) or another treatment for MS you may be able to join an observational research study.

The purpose of the VERISMO Study is to learn more about the long-term effect of ocrelizumab, which may help doctors better know how to use this medication in the future.

Your participation will last for at least 5 years. During this time, information will be collected from your medical records. No particular activities will be required of you, other than keeping your doctor informed about any changes to your health and medications.

Being in this study will not affect how your MS is treated or how often you visit the clinic.

You may be able to take part if you:

- are 18 years of age or older
- have been diagnosed with MS
- are starting or just started treatment with ocrelizumab or another treatment for MS (first dose maximally 30 days before entering the study)
- have not used rituximab in the past.

Want to know more?

If you are interested in learning more about the VERISMO Study, please contact: